在激烈的市场竞争和美国药品降价政策的双重打击下,丹麦制药巨头诺和诺德正面临近十年来最严峻的业绩挑战。诺和诺德预计,按排除汇率影响的固定汇率(CER)计算,2026年全年销售额将较2025年下降5%至13%,远超约1.4%的分析师预期。这一超预期下滑的指引引发市场剧烈反应。诺和诺德CEO Mike Doustdar表示,2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全球GLP-1市场...
Source Link在激烈的市场竞争和美国药品降价政策的双重打击下,丹麦制药巨头诺和诺德正面临近十年来最严峻的业绩挑战。诺和诺德预计,按排除汇率影响的固定汇率(CER)计算,2026年全年销售额将较2025年下降5%至13%,远超约1.4%的分析师预期。这一超预期下滑的指引引发市场剧烈反应。诺和诺德CEO Mike Doustdar表示,2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全球GLP-1市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.